|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||14.53 - 15.15|
|52 Week Range||14.30 - 44.42|
|PE Ratio (TTM)||-2.41|
|Dividend & Yield||1.10 (7.29%)|
|1y Target Est||N/A|
BDSI further said that additional terms of the settlement agreement are confidential and that the agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. A Teva spokeswoman confirmed the settlement agreement and launch date.
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
BT Group PLC (BT), Cardinal Health Inc. (CAH), Teva Pharmaceutical Industries Ltd (TEVA), and Chipotle Mexican Grill Inc. (CMG) have declined to their respective three-year lows.
The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.
Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.
Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market. Mylan's European partner, Synthon, and Alvogen said on Thursday they had received decentralized European approval for a 40 milligram dose of glatiramer acetate, as Copaxone is known generically. Nearly 20 percent of total sales for Teva Pharmaceutical Industries comes from branded Copaxone.
Morgan Stanley analysts downgraded shares of Celgene over concerns of generic drug pressures. Those concerns are not warranted just yet and Celgene is not a sell, Jim Cramer reasoned.
Teva's (TEVA) shares plunged after Mylan announced an earlier-than-expected launch of its generic version of the 40-mg thrice-weekly formulation of its blockbuster multiple sclerosis drug, Copaxone.
U.S. stock futures are trading flat to higher this morning, with Wall Street drifting bullish ahead of a flurry of Federal Reserve speeches and tomorrow’s September jobs data. What’s more, traders will also be keeping a close eye on the release of minutes from the latest European Central Bank policy meeting.
The multiple sclerosis drug Copaxone brought in $4 billion last year for Teva, and generic competition wasn’t expected until at least 2018.
The CNBC IQ100 index is beating the broader market over one year up 22%. Today's leaders include Motorola Solutions, Teva Pharma, GM, Metlife and Prudential.